NeuroPace (NASDAQ:NPCE) Stock Price Target Cut by HC Wainwright

NeuroPace (NASDAQ:NPCE – Get Free Report) had its price target decreased by research analysts at HC Wainwright from $20.00 to $12.00 in a report issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s target price points to a potential upside of 58.73% from the stock’s previous close.

A number of other research analysts also recently issued reports on the company. JPMorgan Chase & Co. downgraded NeuroPace from an “overweight” rating to a “neutral” rating and cut their price target for the company from $20.00 to $9.00 in a report on Friday. Leerink Partners cut NeuroPace from an “outperform” rating to a “market perform” rating and set a $7.00 price objective for the company. in a research note on Friday. Wall Street Zen downgraded NeuroPace from a “hold” rating to a “sell” rating in a research report on Saturday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NeuroPace in a research report on Tuesday, September 15th. Finally, Mizuho assumed coverage on NeuroPace in a research note on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 target price on the stock. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $14.22.

View Our Latest Research Report on NeuroPace

NeuroPace Stock Performance

Shares of NASDAQ:NPCE opened at $7.56 on Monday. The company has a market capitalization of $259.49 million, a price-to-earnings ratio of -13.50 and a beta of 1.98. NeuroPace has a 52 week low of $5.46 and a 52 week high of $19.60. The company has a quick ratio of 4.09, a current ratio of 5.26 and a debt-to-equity ratio of 5.15. The firm has a 50 day moving average of $13.21 and a 200 day moving average of $14.75.

Hedge Funds Weigh In On NeuroPace

A number of large investors have recently made changes to their positions in NPCE. Entropy Technologies LP purchased a new stake in shares of NeuroPace during the 3rd quarter valued at $146,000. Diversified Trust Co purchased a new position in NeuroPace during the 3rd quarter worth $153,000. First Light Asset Management LLC grew its stake in NeuroPace by 16.3% during the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after buying an additional 401,201 shares during the last quarter. Bank of America Corp DE purchased a new position in NeuroPace during the 2nd quarter worth $322,000. Finally, Man Group plc acquired a new position in NeuroPace during the 2nd quarter valued at about $1,336,000. 78.83% of the stock is owned by institutional investors and hedge funds.

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

Recommended Stories

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.